- Anatara Lifesciences (ANR) Receives Ethical Approval to Expand Eligibility Criteria for Its Trials in Irritable Bowel Syndrome (IBS) and Psychological Functioning
- Expansion comes after company faced high screening failure rate due to strict eligibility criteria
- Approval will expand eligibility for all IBS subtypes, as opposed to just the constipation subtype
- The IBS results will not be affected by the change, but the psychological functioning study report is now due early next year.
- Shares are trading in the gray at 6.3 cents apiece as of 2:40 p.m. AEST
Anatara Lifesciences (ANR) has received ethics approval to expand eligibility criteria for its trials in irritable bowel syndrome (IBS) and psychological functioning.
The expansion comes after the company faced a significant selection failure rate due to strict eligibility criteria.
Approval will expand eligibility to all IBS subtypes, as opposed to just the constipation subtype.
This allows for 300 potential participants, who previously could not be enrolled in the trial due to not having diarrhea-predominant IBS.
Psychological functioning trials will now be able to recruit participants from the range of mild to moderate scores on the depression, anxiety and stress scale.
The ANR said the change should not influence the timing of IBS results. However, the psychological functioning study report is now due early next year, as opposed to late this year.
“The delays have been frustrating for all parties involved, including our shareholders, and these should represent the final changes,” Chairman David Brooks said.
The shares were trading in the gray at 6.3 cents apiece as of 2:40 p.m. AEST.